Is COMPASS Pathways (NASDAQ:CMPS) Using Debt Sensibly?

NasdaqGS:CMPS 1 Year Share Price vs Fair Value
NasdaqGS:CMPS 1 Year Share Price vs Fair Value
Explore COMPASS Pathways's Fair Values from the Community and select yours

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' When we think about how risky a company is, we always like to look at its use of debt, since debt overload can lead to ruin. We can see that COMPASS Pathways plc (NASDAQ:CMPS) does use debt in its business. But should shareholders be worried about its use of debt?

Advertisement

When Is Debt A Problem?

Debt assists a business until the business has trouble paying it off, either with new capital or with free cash flow. In the worst case scenario, a company can go bankrupt if it cannot pay its creditors. However, a more frequent (but still costly) occurrence is where a company must issue shares at bargain-basement prices, permanently diluting shareholders, just to shore up its balance sheet. Of course, the upside of debt is that it often represents cheap capital, especially when it replaces dilution in a company with the ability to reinvest at high rates of return. When we think about a company's use of debt, we first look at cash and debt together.

What Is COMPASS Pathways's Net Debt?

As you can see below, at the end of June 2025, COMPASS Pathways had US$30.9m of debt, up from US$29.4m a year ago. Click the image for more detail. However, it does have US$221.9m in cash offsetting this, leading to net cash of US$190.9m.

debt-equity-history-analysis
NasdaqGS:CMPS Debt to Equity History August 7th 2025

A Look At COMPASS Pathways' Liabilities

We can see from the most recent balance sheet that COMPASS Pathways had liabilities of US$31.3m falling due within a year, and liabilities of US$99.7m due beyond that. Offsetting this, it had US$221.9m in cash and US$37.3m in receivables that were due within 12 months. So it can boast US$128.2m more liquid assets than total liabilities.

It's good to see that COMPASS Pathways has plenty of liquidity on its balance sheet, suggesting conservative management of liabilities. Because it has plenty of assets, it is unlikely to have trouble with its lenders. Simply put, the fact that COMPASS Pathways has more cash than debt is arguably a good indication that it can manage its debt safely. When analysing debt levels, the balance sheet is the obvious place to start. But it is future earnings, more than anything, that will determine COMPASS Pathways's ability to maintain a healthy balance sheet going forward. So if you're focused on the future you can check out this free report showing analyst profit forecasts.

Check out our latest analysis for COMPASS Pathways

Given its lack of meaningful operating revenue, COMPASS Pathways shareholders no doubt hope it can fund itself until it has a profitable product.

So How Risky Is COMPASS Pathways?

We have no doubt that loss making companies are, in general, riskier than profitable ones. And the fact is that over the last twelve months COMPASS Pathways lost money at the earnings before interest and tax (EBIT) line. And over the same period it saw negative free cash outflow of US$148m and booked a US$138m accounting loss. However, it has net cash of US$190.9m, so it has a bit of time before it will need more capital. Overall, its balance sheet doesn't seem overly risky, at the moment, but we're always cautious until we see the positive free cash flow. The balance sheet is clearly the area to focus on when you are analysing debt. But ultimately, every company can contain risks that exist outside of the balance sheet. Case in point: We've spotted 4 warning signs for COMPASS Pathways you should be aware of, and 3 of them are a bit concerning.

If you're interested in investing in businesses that can grow profits without the burden of debt, then check out this free list of growing businesses that have net cash on the balance sheet.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

MI
mitchell_lawler
mitchell_lawler

A landmark settlement is meant to punish Meta (META). If the 1998 tobacco deal is any guide, it might protect it.

A landmark settlement is meant to punish Meta (META). If the 1998 tobacco deal is any guide, it might protect it. cover
88
ZO
zoe_vi5fn

Any moat with an opt-out clause for your competitors is just a fence around your own garden.

CO
connor_iwn1g

Worth looking at what previous legal action actually did to Meta rather than reaching for tobacco. The FTC's record five billion dollar privacy fine in 2019 was met with the stock rising, because it came in below fears and removed an open question. GDPR was designed to constrain large platforms and increased their share of the European ad market, because compliance cost fell hardest on small intermediaries. The FTC's antitrust case, the one that could genuinely have broken the company up, was decided in Meta's favour last November. The only thing that ever meaningfully hurt the business was Apple changing a tracking default, and Meta out-spent that too, while the ad-tech firms that could not afford to rebuild disappeared. The pattern is not that Meta survives regulation. It is that regulation keeps costing its smaller competitors more.

Andrew Legget

Great earnings season, but are the earnings real?

Great earnings season, but are the earnings real? cover
At first glance, this was the strongest earnings season in years. But when you look at where the growth actually came from, the story splits into two very different pictures.
10

About NasdaqGS:CMPS

COMPASS Pathways

Operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States.

Excellent balance sheet with low risk.

Similar Companies

Advertisement

Weekly Picks

LO
Lou_Basenese
ONCY logo
Lou_Basenese on Oncolytics Biotech ·

The Team Behind a $2 Billion Johnson & Johnson (JNJ) Deal Just Took Over This $105 Million Cancer Biotech

Fair Value:US$3.575.7% undervalued
22 users have followed this narrative
0 users have commented on this narrative
7 users have liked this narrative
TR
tripledub
Recommended Voice
META logo
tripledub on Meta Platforms ·

The $135 Billion Bet That Should Make Every Shareholder Nervous

Fair Value:US$5862.5% undervalued
59 users have followed this narrative
3 users have commented on this narrative
34 users have liked this narrative
TA
Talos
Emerging Author
VOYG logo
Talos on Voyager Technologies ·

The "Landlord of Orbit" – A Deep Value Play Ahead of the Starlab Era

Fair Value:US$385.291.0% undervalued
58 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative
IV
Emerging Author
UBER logo
Ivoed on Uber Technologies ·

Uber’s Valuation Depends On Who Captures The Economics Of Driverless Rides

Fair Value:US$11633.7% undervalued
11 users have followed this narrative
0 users have commented on this narrative
3 users have liked this narrative

Updated Narratives

RE
AGFB logo
RecMag on Agfa-Gevaert ·

Agfa-Gevaert is a digital and materials turnaround opportunity, with growth potential in ZIRFON, but carrying legacy risks.

Fair Value:€5.3991.4% undervalued
28 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
LU
LunaRodas
FRO logo
LunaRodas on Frontline ·

FRO | Frontline: What They Said vs. What They Did

Fair Value:US$34.0728.4% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
JU
BBWI logo
julio on Bath & Body Works ·

BBWI VALUATION

Fair Value:US$39.7853.1% undervalued
23 users have followed this narrative
1 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

OS
oscargarcia
NVDA logo
oscargarcia on NVIDIA ·

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.

Fair Value:US$28018.6% undervalued
365 users have followed this narrative
9 users have commented on this narrative
16 users have liked this narrative
CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.9120.3% overvalued
213 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative
KI
AMZN logo
KiwiInvest on Amazon.com ·

Amazon's high growth, high tech segments propel its profits, while traditional segments plod along

Fair Value:US$475.0946.1% undervalued
237 users have followed this narrative
1 users have commented on this narrative
8 users have liked this narrative